Plus Therapeutics (PSTV) announced that the FDA has granted Orphan Drug Designation to Reyobiq for the treatment of pediatric malignant gliomas. Notably, the FDA granted orphan designation for malignant glioma more broadly than originally requested, encompassing pediatric ependymoma.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PSTV:
- Plus Therapeutics price target lowered to $12 from $37.50 at Maxim
- Plus CNSide Cerebrospinal Fluid Tumor Cell Enumeration test gets AMA PLA code
- Plus Therapeutics’ treatment of malignant glioma granted FDA orphan designation
- Plus Therapeutics Enacts Reverse Stock Split to Maintain Listing
- Plus Therapeutics Inc (USA) trading halted, news pending